Medical Coverage Policies

Systems Pathology in Predicting Prostate Cancer Treatment

Description:
There are a number of predictive tools available to assess an individual patient's risk for prostate cancer. They include biopsy Gleason grade and score based on changes in tissue morphology, the number of positive tumor cores, preoperative prostate-specific antigen (PSA) level, and clinical tumor stage. Yet, no one risk assessment method can accurately predict a patient's outcome post treatment.

The current challenge to predicting an individual's risk is complicated by the subjectivity of these analysis and which cannot provide quantitative results. Systems pathology (Prostate PX) is an attempt at overcoming these deficiencies by integrating information from histologic, molecular, and clinical information to predict cancer recurrence by integrating three advanced technologies. 1). Image analysis in which a digital image of cancer tissue is used to generate various statistical measurements. 2). Biomarker detection, such as multiplexed in situ protein detection using fluorescently tagged antibodies and analysis via spectral imaging. 3). Clinical information, such as the Gleason score, pathologic stage, or PSA values. Data extracted from these tools provide results that can be analyzed by mathematic formulas or algorithms related to data mining, pattern recognition and statistical analysis. By using the patient's prostatectomy tissue, disease recurrence can be assessed, as either PSA recurrence or disease progression for up to 5 years post-surgery. The integration of all data sets pertaining to one patient can produce a personalized and individually predictive diagnosis and as a consequence, a therapy that is tailored to the individual.

At this time, the data reviewed to evaluate the effectiveness of this novel approach is insufficient to determine if systems pathology is more useful as an assessment tool to measure a patient's risk for prostate cancer as compared to other established methods.

Medical Criteria:
Not applicable.

Policy:
Systems pathology using Prostate PX testing as a predictive tool to determine cancer therapy is considered not medically necessary as the clinical data is insufficient to determine if it is more useful as an assessment tool to measure a patient's risk for prostate cancer as compared to other established methods.

Coverage:
There is not an established code which adequately describes the procedure therefore the provider should file using the unlisted code 88399. An "Unlisted Procedure Claim" form must be completed and the required supporting documentation provided.

Coding:
88399

Also known as:
Prostate PX Testing

Publications:
Provider Update, January 2010

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgement in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment.
at their own expense. Please refer to your participation agreement(s) for the applicable provisions.

This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice.